Nivolumab Is Effective and Reasonably Safe in Relapsed or Refractory Hodgkin's Lymphoma after Allogeneic Hematopoietic Cell Transplantation: A Study from the Lysa and SFGM-TC
Charles Herbaux(Centre Hospitalier Universitaire de Lille), Franck Morschhauser(Hôpital Claude Huriez), Hélène Demarquette(Ikerbasque), Roch Houot(Inserm), Anne Thiebaut‐Bertrand(Délégation Paris 7), Ibrahim Yakoub‐Agha(Inserm), Guillaume Manson(Hôpital Pontchaillou), Krimo Bouabdallah(Centre Hospitalier Universitaire de Bordeaux), Hervé Ghesquières(Université Claude Bernard Lyon 1), Loïc Ysebaert(Institut universitaire du cancer de Toulouse Oncopole), Pauline Brice(Hôpital Saint-Louis), Jordan Gauthier(Seattle Cancer Care Alliance), Luc Matthieu Fornecker(Hôpital d'Hautepierre), Eileen M. Boyle(BMW (Germany))
Cited by 36
Related Papers
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
|The Lancet|2021|795
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
|The Lancet|2018|733
Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2022|718
Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma
|Journal of Clinical Oncology|2015|564